There is evidence that PPARγ agonists could improve the neurological outcomes in the variable central nervous system diseases, such as Alzheimer’s disease[34], multiple sclerosis[35], Parkinson’s disease[36], and acute cerebral ischemia[37]. The gene discussed is PPARG; the disease is early-onset autosomal dominant Alzheimer disease.